重组人p53基因腺病毒注射液在原发性肝癌介入治疗中的临床研究

目的:研究重组人p53腺病毒注射液（商品名:今又生）在原发性肝癌介入治疗中的安全性及有效性。方法:61例中晚期原发性肝癌患者，分两组介入治疗:对照组:碘油+化疗药（5-FU+EPI+DDP）；治疗组:碘油+化疗药（5-FU+EPI+DDP）+重组人p53基因腺病毒注射液；每4周一次，连用3次。结果:不论是对照组还是治疗组，毒副反应不大，耐受性良好，生活质量均有一定的提高；治疗后两组均能使原发性肝癌的肿瘤标志物AFP下降，但治疗组下降明显；治疗组的有效率（82.76%）明显高于对照组（59.38%），统计学检验差异显著。结论:今又生介入治疗原发性肝癌安全有效，值得推广。

The effect of restructuring of p53 adenovirus injectionin the primary liver cancer under-wenttranscatheter arterial chemoembolization(TACE)

Objective:To study the efficacy and safety of restructuring of p53 adenovirus injecttion in the primary liver cancer underwenttranscatheter arterial chemoembolization，TACE.Methods:Sixty one patients were diagnosed as primary liver cancer,pathologically.All patients underwent transcatheter arterial chemoembolization，TACE and were randomized divided into two groups,the control group was treated by iodine oil+chemotherapy drugs（5-FU+EPI+DDP）,the treatment group withiodine oil+chemotherapy drugs（5-FU+EPI+DDP）+restructuring of p53 adenovirus injection.The efficacy，quality of life(QOL)，and adverse reactions were evaluated．Results:In two groups,the reliability safety was similar,life quality was enhanced,and the tumor mark was decinling.The effective rates of two groups were 59.38% and 82.76%,the treatment group was superior to the control group(P＜0.05).Conclusion:Using restructuring of p53 adenovirus injectionon the interventional therapyin the primary liver cancer,can increase effective rate.